NTLA — INTELLIA THERAPEUTICS Share News
0.000.00%
Last trade - 00:00- $1.56bn
- $1.13bn
- $67.67m
Brief: Intellia Therapeutics Q4 Net Income USD -128.898 Million
Intellia Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40
U.S. STOCKS ON THE MOVE-Astronics, Nike, Climb Bio
Intellia declines on plans to stop development of lung disease therapy
Intellia declines on plans to stop development of lung disease therapy
Brief: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To Nexiguran Ziclumeran
U.S. STOCKS ON THE MOVE-Henry Schein Inc, Palantir Technologies, Uber Technologies
U.S. STOCKS ON THE MOVE-Tesla Inc, Palantir Technologies and Super Micro Computer Inc
U.S. STOCKS ON THE MOVE-Silver Miners, Intellia, Robinhood
Intellia surges on promising early-stage data for gene editing therapy
Intellia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Intellia Therapeutics Q3 Net Income USD -135.712 Million
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group
U.S. STOCKS ON THE MOVE-Teck Resources, Nasdaq, T-Mobile
Intellia falls as mid-stage data from gene therapy study fails to impress
Brief: Intellia Therapeutics Announces Initiation Of Haelo Phase 3 Study Of Ntla-2002